- SHL Medical and GRAM announce a partnership to introduce fill-finish services for the Maggie® 5.0 autoinjector.
- The collaboration combines SHL’s drug delivery expertise with GRAM’s experience in sterile fill-finish solutions for large-volume containers.
SHL Medical, a global provider of advanced drug delivery systems, has announced a strategic partnership with Grand River Aseptic Manufacturing (GRAM), a contract development and manufacturing organization (CDMO) specializing in sterile injectable biologics. This collaboration aims to introduce fill-finish services for the Ready-To-Use (RTU) cartridge of the Maggie® 5.0 mL autoinjector.
The Maggie® 5.0 is an extension of SHL’s existing 3.0 mL autoinjector platform, designed for large-volume drug delivery. It is equipped with SHL’s Needle Isolation Technology (NIT®), which enhances safety and ease of use by eliminating the need for patients to manually attach the needle. This two-step system keeps the needle permanently concealed.
The partnership between SHL and GRAM brings together expertise in drug delivery and fill-finish processes. GRAM’s experience with scalable pharmaceutical manufacturing and aseptic filling will complement SHL’s innovative autoinjector solutions, offering pharmaceutical companies a streamlined, integrated solution. This collaboration aims to speed up market entry for the Maggie® 5.0 autoinjector by providing an established supply chain.
Markus Puusepp, SHL Medical’s Chief Growth Officer, said, “The partnership with GRAM underlines our commitment to providing comprehensive solutions that address the growing needs of our pharmaceutical partners. By combining SHL’s innovative drug delivery systems with GRAM’s expertise in aseptic fill-finish, we are well-positioned to bring effective solutions to market more efficiently.”
Dave Powell, Vice President of Business Development at GRAM, also expressed his excitement: “This partnership supports GRAM’s vision of being recognized as a CDMO leader in both fill and finish services and drug delivery solutions. Together, we are creating a streamlined solution that will offer significant value to pharmaceutical companies and patients.”
Overview of outsourcing trends 
